Přihlásit se Zaregistrujte se zdarma

1letý cíl společnosti AC Immune SA

Jaká je hodnota metriky 1letý cíl společnosti AC Immune SA?

Hodnota metriky 1letý cíl společnosti AC Immune SA je $12 +275.94%

Jaká je definice metriky 1letý cíl?

1-letý cíl (1-year target) je analytiky předpokládaná cena akcie za rok od dnešního dne.

One year target is an estimate of a stock price for a point in time equal to a year from the current date. The price level most often reflects the collective opinion of different analysts on where the stock will be trading a year from now. For an analyst to identify an individual estimate, they have to project what a company’s business will look like in a year, typically focusing on revenue and other significant factors. They also consider the willingness of investors to pay a certain price. While the average or median recommendation may be predictive and reflect the actual future value, the results are usually not extremely successful.

1letý cíl společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností AC Immune SA

Čemu se věnuje společnost AC Immune SA?

ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor

Firmy s metrikou 1letý cíl podobnou společnosti AC Immune SA